Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial - Concepedia

Concepedia

Publication | Closed Access

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

1K

Citations

30

References

2014

Year

Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens‐Uwe Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber,

The Lancet Oncology

Gbg 66Breast OncologyMedicineRandomised Phase 2Neoadjuvant CarboplatinPathologyBreast CancerCancer TreatmentOncologyRadiation Oncology

References

	Year	Citations

Page 1

Page 1